ClinicalTrials.gg
Not yet recruitingNCT07908446ARTISTRY-3Updated Nov 2, 2026

Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV

A Phase 4 interventional study of BIC/LEN FDC and Lenacapavir in HIV-1 Infection, sponsored by Gilead Sciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Updated Nov 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to assess the effectiveness and safety of switching to bictegravir/lenacapavir (BIC/LEN) fixed-dose combination (FDC) compared with continuing stable baseline regimens (SBR) in virologically suppressed people with HIV.

The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) fixed-dose combination (FDC) tablets versus continuing their stable baseline regimen (SBR) in virologically suppressed people with HIV.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • Bictegravir
  • Lenacapavir
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently receiving a SBR defined as (1) integrase strand-transfer inhibitor (INSTI) + 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs) (excluding bictegravir/emtricitabine/tenofovir alafenamide (BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF)), (2) boosted-protease inhibitor (PI) + 2 NRTIs, (3) nonnucleoside reverse transcriptase inhibitor (NNRTI) + 2 NRTIs, (4) dolutegravir (DTG)/RPV or (5) cabotegravir (CAB)/rilpivirine (RPV) for at least 3 months without switch prior to screening, and willing to continue their SBR through at least Week 24.
  • -1 RNA \< 50 copies/mL for ≥ 3 months before screening
  • Estimated (eCLcr) rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) at screening
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening

Key Exclusion Criteria:

  • Actively pregnant or breastfeeding (nursing)
  • Chronic virus (HBV)
  • Known to the study drug, its metabolites, or formulation .
  • Currently receiving renal replacement therapy (eg, hemodialysis)
  • Documented or suspected resistance to BIC
  • History of, or current severe decompensated cirrhosis
  • Requirement for ongoing therapy with any prohibited medications listed for BIC/LEN FDC
  • Prior use of, or exposure to, LEN
  • Ongoing treatment with BIC/FTC/TAF

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Immediate Switch Arm: BIC/LEN FDC

    Participants will switch to BIC/LEN (75 mg/50mg) FDC tablets once daily starting on Day 1. Participants will receive a 2-day oral loading dose regimen of LEN 600 mg on Days 1 and 2, in addition to the once-daily doses of BIC/LEN FDC starting on Day 1, up to Week 48.

    Drug: BIC/LEN FDC · Drug: Lenacapavir

  • Active comparator
    Delayed Switch Arm: Stable Baseline Regimen (SBR)

    Participants will remain on their existing SBR antiretroviral therapy (ART) regimen from Day 1 through Week 24. At Week 24, they will switch to BIC/LEN (75 mg/50 mg) FDC tablets once daily. At the time of BIC/LEN FDC initiation, participants will receive a 2-day oral loading dose regimen of LEN 600 mg on Day 1 and 2, in addition to the once-daily doses of BIC/LEN FDC starting at the time of switch, up to Week 48.

    Drug: BIC/LEN FDC · Drug: Lenacapavir · Drug: SBR

Interventions

  • DrugBIC/LEN FDC

    Drug page: Bictegravir

    Tablet administered orally

    Also known as: Bixlenvo™

  • Tablet administered orally

    Also known as: LEN

  • DrugSBR

    SBR will include approved ARTs like: integrase strand-transfer inhibitor (INSTI) + 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs), excluding bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), boosted-protease inhibitor (PI) + 2 NRTIs, nonnucleoside reverse transcriptase inhibitor (NNRTI) + 2 NRTIs, or dolutegravir (DTG)/rilpivirine (RPV) or cabotegravir (CAB) + RPV

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 24, as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm

    Time frame: Week 24

Secondary outcomes

  1. Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 using the US FDA-defined snapshot algorithm

    Time frame: Week 48

  2. Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the US FDA-Defined Snapshot Algorithm

    Time frame: Week 24

  3. Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the US FDA-Defined Snapshot Algorithm

    Time frame: Week 48

  4. Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24

    Time frame: Baseline, Week 24

  5. Change From Baseline in CD4 Cell Count at Week 48

    Time frame: Baseline, Week 48

  6. Percentage of Participants Experiencing Treatment-Emergent Grade 3 or 4 Adverse Events (AEs)

    Time frame: First dose date up to Week 48 plus 60 days

  7. Percentage of Participants Experiencing Treatment-Emergent Serious Adverse events (SAEs)

    Time frame: First dose date up to Week 48 plus 60 days

  8. Percentage of Participants Experiencing Treatment-Emergent AEs Leading to Discontinuation of Study Drug Through Week 48

    Time frame: Up to week 48

  9. Change From Baseline in Patient-Reported Experience and Satisfaction Score, as Assessed by the Questionnaire to Understand the Experience and Satisfaction in a Study in HIV-Treatment (QUEST-HIV-T) at Week 24

    The QUEST-HIV-T is a patient-reported outcome (PRO) measure that evaluates experience and satisfaction in a clinical study for HIV. The measure consists of 16-item that is intended to be completed by PWH during an active treatment period using a recall period of "the past 7 days." The QUEST-HIV-T utilizes 5-point verbal descriptor scales (Not at all-Extremely, Very satisfied-Very dissatisfied).

    Time frame: Baseline, Week 24

  10. Change From Baseline in Patient-Reported Experience and Satisfaction Score, as Assessed by the Questionnaire to Understand the Experience and Satisfaction in a Study in HIV-Treatment (QUEST-HIV-T) at Week 48

    Time frame: Baseline, Week 48

  11. Proportion of Participants Reporting a Preference for BIC/LEN FDC Compared with Previous SBR, as Assessed by the HIV-Treatment Preference Questionnaire (HIV-TPQ) at Week 48

    The HIV-Treatment Preference Questionnaire (HIV-TPQ) is a PRO measure designed to evaluate participants' preference between treatment received prior to the study entry and the clinical study intervention. The HIV-TPQ assesses preference across multiple treatment attributes. The overall preference item uses a 3-point categorical response scale (Treatment before the study, Study treatment, No preference). All remaining items use a 5-point verbal descriptor scale (Very much prefer treatment before the study-Very much prefer study intervention).

    Time frame: Week 48

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 2, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2028
CompletionEst.
Nov 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07908446
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Lenacapavir

Start the discussion